FLT3L-Fc fusion protein therapy(Genentech/Evotec)

N/A

Report date: 2024/01/04 16:02:48

Base Information

Drug NameFLT3L-Fc fusion protein therapy(Genentech/Evotec)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionFms-related tyrosine kinase 3 ligand stimulants
TargetsFms-related tyrosine kinase 3 ligand
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenentech IncEvotec
China Registration ClassN/A

Develop Information

Active CompaniesEvotecGenentech Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A